# colorectal cancer - deepseek-v4-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 2
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 38538
- Completion tokens: 16058
- Reasoning tokens: 0
- Total tokens: 54596
- API requests reported: 3
- Elapsed seconds: 108.776
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 2/5; original repeat 2; model vendor: DeepSeek

---
# Multidimensional Interpretation of Prognostic Transcriptomic Results in Colorectal Cancer (Overall Survival)

---

## 1. Overall Biological Interpretation

This prognostic analysis of colorectal cancer (CRC) tumor tissue identified 100 genes significantly associated with overall survival (FDR ≤ 0.076 across the full list; 71 genes at FDR ≤ 0.05; 8 genes at FDR ≤ 0.01). The cohort splits into 54 risk-associated genes (HR > 1) and 46 protective-associated genes (HR < 1), producing a balanced but directionally informative landscape.

The dominant biological theme is a **mesenchymal/stromal and EMT-like transcriptional program conferring poor prognosis**, evidenced by risk-associated genes including ZEB1-AS1, TPM4, ITGBL1, DCBLD2, NT5E, MSLN, LRRC8A, and MAP1B. This is counterbalanced by a **protective program centered on differentiated intestinal epithelial identity and metabolic homeostasis**, represented by CDX2, CDX1, MYB, LGALS4, and multiple mitochondrial/oxidative metabolism genes (NDUFA9, ATP5B, ATP5G1, CS, COA3, TIMM13).

A second major theme is **TGF-β/BMP and activin signaling**, anchored by INHBB (the strongest risk gene, HR = 1.433, FDR = 0.0011) and reinforced by PTPN14, AKT3, and downstream effectors. A third theme involves **proliferation and cell-cycle control**, with protective genes GMNN, MYB, and RAB11FIP4 suggesting that loss of regulated proliferation machinery associates with worse outcomes. Finally, **immune and inflammatory modulation** appears through protective LGALS9, TAPBPL, and CCL15, alongside risk-associated NT5E and GADD45B.

The overall picture is consistent with a model where **loss of intestinal differentiation identity, acquisition of mesenchymal features, and activation of TGF-β superfamily signaling collectively define a poor-prognosis CRC subtype**.

---

## 2. Core Biological Programs

### Program 1: EMT and Mesenchymal Transition
- **Direction:** Risk-associated (poor OS)
- **Major supporting genes:** ZEB1-AS1 (HR = 1.372, FDR = 0.0086), TPM4 (HR = 1.364, FDR = 0.0089), ITGBL1 (HR = 1.299, FDR = 0.0306), DCBLD2 (HR = 1.408, FDR = 0.0086), MAP1B (HR = 1.327, FDR = 0.0472), NT5E (HR = 1.313, FDR = 0.0394)
- **Pathway:** Hallmark Epithelial-Mesenchymal Transition; Reactome R-HSA-1474244 (Extracellular matrix organization)
- **Explanation:** ZEB1-AS1 is the antisense transcript of ZEB1, a master EMT transcription factor. TPM4 encodes a tropomyosin isoform upregulated in mesenchymal cells. ITGBL1 is a secreted integrin-binding protein associated with TGF-β-driven metastasis. DCBLD2 and MAP1B are cytoskeletal/structural genes with EMT associations. The collective direction of these genes toward higher HR indicates that mesenchymal features predict worse survival.
- **Evidence strength:** Moderate-strong. Multiple independent genes converge on the same program with consistent direction. However, no formal pathway enrichment statistic was computed in this analysis; the program is inferred from gene-level annotations and literature.
- **Limitations:** EMT programs in bulk tumor tissue may reflect stromal contamination rather than tumor-cell-intrinsic EMT. Without cell-type deconvolution, the cellular origin of these signals is ambiguous.

### Program 2: TGF-β/Activin/BMP Signaling
- **Direction:** Risk-associated (poor OS)
- **Major supporting genes:** INHBB (HR = 1.433, FDR = 0.0011), PTPN14 (HR = 1.362, FDR = 0.0250), AKT3 (HR = 1.318, FDR = 0.0388), DCBLD2 (HR = 1.408, FDR = 0.0086), ITGBL1 (HR = 1.299, FDR = 0.0306)
- **Pathway:** KEGG hsa04350 (TGF-beta signaling pathway); Reactome R-HSA-2173789 (TGF-beta receptor signaling)
- **Explanation:** INHBB encodes the inhibin βB subunit, which dimerizes to form activin B, a TGF-β superfamily ligand with established roles in CRC progression. Recent literature specifically links high INHBB expression in CRC to poor prognosis and malignant phenotypes (Europe PMC 41992239). PTPN14 is a negative regulator of YAP, which intersects with TGF-β signaling. ITGBL1 is functionally linked to TGF-β-induced EMT in multiple cancer types. The convergence of these genes on TGF-β superfamily signaling provides a coherent mechanistic framework.
- **Evidence strength:** Moderate. INHBB is the single most significant gene in the dataset and has direct literature support in CRC. The other genes are more circumstantial, and their connection to TGF-β signaling is inferred from pathway annotations rather than demonstrated in this cohort.
- **Limitations:** TGF-β signaling is context-dependent in CRC—tumor-suppressive in early stages, pro-metastatic in later stages. The prognostic direction here (risk) is consistent with the pro-metastatic role, but stage information is not available in the input.

### Program 3: Loss of Intestinal Differentiation Identity
- **Direction:** Protective-associated (better OS)
- **Major supporting genes:** CDX2 (HR = 0.748, FDR = 0.0355), CDX1 (HR = 0.781, FDR = 0.0573), MYB (HR = 0.771, FDR = 0.0192), LGALS4 (HR = 0.771, FDR = 0.0512), LGALS9 (HR = 0.753, FDR = 0.0420)
- **Pathway:** GO:0030855 (epithelial cell differentiation); KEGG hsa04974 (Protein digestion and absorption)
- **Explanation:** CDX2 and CDX1 are master transcription factors for intestinal differentiation. Loss of CDX2 is a well-established marker of aggressive, poorly differentiated CRC. MYB is a transcription factor that cooperates with CDX2 in intestinal differentiation programs. LGALS4 (galectin-4) is expressed in differentiated intestinal epithelium and its downregulation is associated with poor differentiation. The protective direction (HR < 1) of these genes indicates that **preserved intestinal differentiation is associated with better survival**.
- **Evidence strength:** Moderate-strong. CDX2 loss in CRC is extensively documented in the literature (PMID 30631044). The direction is consistent with established biology.
- **Limitations:** CDX2 expression in bulk tissue may be diluted by stromal content; the protective signal could reflect higher tumor purity or better-differentiated tumors rather than a direct mechanistic effect.

### Program 4: Mitochondrial Oxidative Metabolism
- **Direction:** Protective-associated (better OS)
- **Major supporting genes:** NDUFA9 (HR = 0.689, FDR = 0.0086), ATP5B (HR = 0.748, FDR = 0.0593), ATP5G1 (HR = 0.747, FDR = 0.0519), CS (HR = 0.754, FDR = 0.0388), COA3 (HR = 0.744, FDR = 0.0434), TIMM13 (HR = 0.751, FDR = 0.0394), ATP23 (HR = 0.688, FDR = 0.0066)
- **Pathway:** Reactome R-HSA-611105 (Respiratory electron transport); KEGG hsa00190 (Oxidative phosphorylation)
- **Explanation:** Multiple subunits of the electron transport chain (NDUFA9, ATP5B, ATP5G1), the TCA cycle enzyme CS, and mitochondrial assembly factors (COA3, TIMM13, ATP23) all show protective HRs. This consistent direction across multiple independent mitochondrial genes suggests that **preserved oxidative phosphorylation is associated with better survival**, potentially reflecting a less glycolytic, less aggressive tumor phenotype.
- **Evidence strength:** Moderate. The coherence across multiple genes is notable, but the individual FDRs are modest (most between 0.04 and 0.06). No formal pathway enrichment statistic was computed.
- **Limitations:** Mitochondrial gene expression in bulk tissue may reflect stromal or immune cell content rather than tumor-cell metabolism. ATP23 is also involved in prohibitin-related processes (PMID 17135288), suggesting broader mitochondrial quality-control functions.

### Program 5: Immune Modulation and Antigen Presentation
- **Direction:** Mixed (protective and risk components)
- **Major supporting genes:** Protective: LGALS9 (HR = 0.753, FDR = 0.0420), TAPBPL (HR = 0.711, FDR = 0.0192), CCL15 (HR = 0.753, FDR = 0.0355), CASP6 (HR = 0.768, FDR = 0.0453); Risk: NT5E (HR = 1.313, FDR = 0.0394), GADD45B (HR = 1.324, FDR = 0.0630)
- **Pathway:** GO:2000404 (regulation of T cell migration); Reactome R-HSA-1236974 (Antigen processing-Cross presentation)
- **Explanation:** LGALS9 (galectin-9) is a ligand for TIM-3 and has complex immunomodulatory roles; its protective direction is consistent with anti-tumor immune activity. TAPBPL is involved in antigen presentation. NT5E (CD73) is an immunosuppressive ectoenzyme that generates adenosine; its risk direction is consistent with its role in immune evasion (PMID 36480312). The opposing directions of immune-related genes suggest that **the balance between immune activation and immunosuppression is prognostically relevant**.
- **Evidence strength:** Moderate. The individual genes have clear immune annotations, but the program is more heterogeneous than the others, with both protective and risk components.
- **Limitations:** Bulk-tissue immune gene expression is heavily influenced by immune cell infiltration, which varies with tumor stage and location. The direction of CCL15 is counterintuitive given its reported pro-inflammatory role; this may reflect cell-type-specific effects.

---

## 3. Key Genes and Interaction Modules

### 1. INHBB (HR = 1.433, FDR = 0.0011) — Risk
- **Statistical direction:** Strongest risk-associated gene in the dataset.
- **Biological role:** Encodes activin/inhibin βB subunit; activates TGF-β/activin signaling. Recent literature directly links high INHBB in CRC to poor prognosis and malignant phenotypes (Europe PMC 41992239).
- **Gene relationships:** Pathway co-membership with TGF-β superfamily signaling (ACVR1B/ACVR2B receptors). Indirect/putative relationship with ITGBL1 and PTPN14 through shared TGF-β pathway involvement.
- **Relationship types:** Pathway co-membership (TGF-β signaling); indirect/putative crosstalk with EMT regulators. No direct physical interaction data from the input.

### 2. CDX2 (HR = 0.748, FDR = 0.0355) — Protective
- **Statistical direction:** Protective; higher expression associated with better OS.
- **Biological role:** Master intestinal differentiation transcription factor; suppresses Wnt/β-catenin signaling via GSK-3β and Axin2 transactivation (PMID 30631044).
- **Gene relationships:** Regulatory interaction with MYB (co-regulators of intestinal differentiation); pathway co-membership with CDX1 in intestinal development.
- **Relationship types:** Regulatory interaction (transcription factor cooperation with MYB); pathway co-membership with CDX1. No direct physical interaction evidence from the input.

### 3. ZEB1-AS1 (HR = 1.372, FDR = 0.0086) — Risk
- **Statistical direction:** Risk-associated; higher expression associated with worse OS.
- **Biological role:** Antisense transcript of ZEB1, a master EMT transcription factor. Likely regulates ZEB1 expression.
- **Gene relationships:** Regulatory interaction with ZEB1 (antisense regulation); pathway co-membership with EMT program alongside TPM4, ITGBL1, DCBLD2.
- **Relationship types:** Regulatory interaction (antisense regulation of ZEB1); pathway co-membership (EMT). No direct physical interaction with ZEB1 protein is implied.

### 4. NDUFA9 (HR = 0.689, FDR = 0.0086) — Protective
- **Statistical direction:** One of the strongest protective genes.
- **Biological role:** Complex I subunit of the mitochondrial electron transport chain.
- **Gene relationships:** Pathway co-membership with ATP5B, ATP5G1, CS, COA3, TIMM13 in oxidative phosphorylation. STRING network evidence connects COA3 and ILVBL via MT-CO1, suggesting mitochondrial complex assembly coordination.
- **Relationship types:** Pathway co-membership (oxidative phosphorylation); protein interaction evidence from STRING for mitochondrial complex partners (indirect, network-derived).

### 5. NT5E/CD73 (HR = 1.313, FDR = 0.0394) — Risk
- **Statistical direction:** Risk-associated.
- **Biological role:** Ecto-5'-nucleotidase; generates immunosuppressive adenosine; established biomarker for cancer prognosis and immunotherapy response (PMID 36480312).
- **Gene relationships:** Indirect/putative relationship with LGALS9 through opposing immune modulation; pathway co-membership with adenosine signaling.
- **Relationship types:** Pathway co-membership (immune regulation); indirect/putative functional opposition to LGALS9. No direct physical interaction evidence from the input.

### 6. PTPN14 (HR = 1.362, FDR = 0.0250) — Risk
- **Statistical direction:** Risk-associated.
- **Biological role:** Protein tyrosine phosphatase; negative regulator of YAP/TAZ signaling. Its risk direction suggests that higher expression may paradoxically promote tumor progression, or that its YAP-regulatory function is disrupted in CRC.
- **Gene relationships:** Regulatory interaction with YAP/TAZ (phosphatase-mediated regulation); pathway co-membership with Hippo and TGF-β signaling.
- **Relationship types:** Regulatory interaction (YAP dephosphorylation); pathway co-membership. No direct physical interaction with INHBB or AKT3 from the input.

### 7. AKT3 (HR = 1.318, FDR = 0.0388) — Risk
- **Statistical direction:** Risk-associated (7 rows in ledger, indicating multiple probes).
- **Biological role:** PI3K/AKT signaling; isoform-specific roles in cancer progression.
- **Gene relationships:** Pathway co-membership with PI3K-AKT-mTOR signaling; indirect/putative crosstalk with TGF-β signaling through SMAD-AKT interactions.
- **Relationship types:** Pathway co-membership (PI3K-AKT); indirect/putative crosstalk. No direct physical interaction with INHBB from the input.

### 8. MYB (HR = 0.771, FDR = 0.0192) — Protective
- **Statistical direction:** Protective.
- **Biological role:** Transcription factor essential for intestinal homeostasis; cooperates with CDX2. STRING evidence indicates interactions with CREBBP, EP300, and CEBPB (confidence > 0.94).
- **Gene relationships:** Regulatory interaction with CDX2 (transcription factor cooperation); direct physical interaction with CREBBP/EP300 (STRING-derived).
- **Relationship types:** Regulatory interaction (CDX2 cooperation); direct physical interaction with CREBBP/EP300 (STRING evidence, high confidence). These are distinct relationship types and should not be conflated.

### 9. MSLN (HR = 1.313, FDR = 0.0451) — Risk
- **Statistical direction:** Risk-associated.
- **Biological role:** Mesothelin; a cell-surface glycoprotein overexpressed in several cancers. Emerging as an immunotherapy target; CAR-T cells targeting mesothelin are being tested in CRC organoid models (Europe PMC 42363170).
- **Gene relationships:** Pathway co-membership with tumor-associated antigen presentation; indirect/putative relationship with immune evasion.
- **Relationship types:** Pathway co-membership; indirect/putative. No direct interaction evidence from the input.

### 10. LRRC8A (HR = 1.376, FDR = 0.0250) — Risk
- **Statistical direction:** Risk-associated.
- **Biological role:** Volume-regulated anion channel; implicated in drug resistance and cell volume regulation in cancer.
- **Gene relationships:** Pathway co-membership with LRRC8 family channels; indirect/putative relationship with chemotherapy resistance.
- **Relationship types:** Pathway co-membership (volume-regulated anion channels); indirect/putative. No direct interaction evidence from the input.

---

## 4. Validation Priorities

### Priority 1: EMT/Stromal Contribution to Risk Signal
- **Classification:** Confounding or composition check
- **Why:** The EMT program (ZEB1-AS1, TPM4, ITGBL1, DCBLD2) could reflect stromal or fibroblast content rather than tumor-cell-intrinsic EMT. This is the most important confounder in bulk-tissue CRC transcriptomics.
- **Current dataset evidence:** Risk-associated HRs for EMT genes; no cell-type deconvolution available.
- **External evidence:** EMT genes are canonically expressed in cancer-associated fibroblasts and mesenchymal cells; CRC consensus molecular subtype 4 (CMS4) is defined by stromal activation and has the worst prognosis.
- **Next step:** Perform cell-type deconvolution (CIBERSORTx, MCP-counter, or single-cell RNA-seq validation) to determine whether the EMT risk signal is tumor-intrinsic or stromal-derived.
- **Conclusion status:** Exploratory hypothesis

### Priority 2: INHBB/Activin Signaling as a Mechanistic Driver
- **Classification:** Mechanistic hypothesis
- **Why:** INHBB is the strongest risk gene (HR = 1.433, FDR = 0.0011) and has direct CRC literature support. Activin signaling is druggable and mechanistically linked to EMT.
- **Current dataset evidence:** Strong HR and FDR; pathway co-membership with TGF-β superfamily.
- **External evidence:** Europe PMC 41992239 directly links high INHBB expression in CRC to poor prognosis and malignant phenotypes. Activin receptor kinase inhibitors exist in development.
- **Next step:** Functional validation in CRC cell lines and organoids—knockdown or inhibition of INHBB/activin signaling and assessment of EMT markers, invasion, and proliferation.
- **Conclusion status:** Supported hypothesis

### Priority 3: CDX2 Loss as a Prognostic Biomarker
- **Classification:** Biomarker
- **Why:** CDX2 loss is a well-established marker of aggressive CRC. Its protective direction here (HR = 0.748) is consistent with extensive literature.
- **Current dataset evidence:** Protective HR (0.748, FDR = 0.0355); co-occurrence with CDX1 and MYB in the same protective direction.
- **External evidence:** PMID 30631044 demonstrates CDX2 suppresses Wnt/β-catenin signaling in colon cancer; multiple clinical studies link CDX2 loss to poor prognosis.
- **Next step:** Immunohistochemical validation of CDX2 protein in an independent CRC cohort, stratified by stage and MSI status.
- **Conclusion status:** Supported hypothesis (the association is established in the literature; the current dataset provides supporting direction-specific evidence)

### Priority 4: NT5E/CD73 as an Immunotherapy-Relevant Target
- **Classification:** Therapeutic target
- **Why:** NT5E (CD73) is a well-validated immunosuppressive target with clinical-stage inhibitors. Its risk association here is consistent with immune evasion.
- **Current dataset evidence:** Risk-associated HR (1.313, FDR = 0.0394).
- **External evidence:** PMID 36480312 identifies CD73/NT5E as a prognostic biomarker across multiple cancer types. Anti-CD73 antibodies are in clinical trials.
- **Next step:** Assess NT5E protein expression by IHC in CRC tumors and correlate with immune infiltration and survival. Consider whether CD73 inhibition is testable in CRC models.
- **Conclusion status:** Supported hypothesis (target relevance is established; efficacy in this specific CRC context requires validation). The existence of CD73-targeting drugs does not by itself demonstrate efficacy in CRC.

### Priority 5: Mitochondrial Program Directionality
- **Classification:** Confounding or composition check / Mechanistic hypothesis
- **Why:** The protective direction of multiple mitochondrial genes (NDUFA9, ATP5B, ATP5G1, CS, COA3, TIMM13, ATP23) could reflect either a genuine metabolic phenotype or differential cellular composition (e.g., higher immune/stromal content in better-prognosis tumors).
- **Current dataset evidence:** Consistent protective HRs across 7+ mitochondrial genes.
- **External evidence:** Glycolytic switch (Warburg effect) is a hallmark of aggressive cancer; however, some studies show preserved oxidative metabolism in certain CRC subtypes.
- **Next step:** Measure mitochondrial function (Seahorse assays) in CRC cell lines with high vs. low expression of these genes; perform spatial transcriptomics to localize mitochondrial gene expression to tumor vs. stromal compartments.
- **Conclusion status:** Exploratory hypothesis

---

## 5. Evidence Grounding

### Evidence Types and Sources

| Evidence Category | Genes/Programs | Source | Independence Notes |
|---|---|---|---|
| **Direct input evidence** | All 100 genes; HR, P, FDR values | User-supplied table | Authoritative for this cohort; no external replication |
| **Pathway/ontology evidence** | GO: Regulation of phospholipase C activity, Microtubule anchoring, Regulation of T cell migration; KEGG: Glyoxylate metabolism, Melanoma, Gastric cancer | Question-time GO/KEGG batch | These annotations are contextual; they may reflect overlapping gene sets and were not computed as enrichment statistics in this analysis |
| **Protein interaction evidence** | STRING edges (42 edges); specific interactions: ARG1-ASL-CRYM, CS-ACSS2-ILVBL, DOCK6/7/8-LRCH1/3, MT-CO1-COA3-ILVBL | STRING | STRING integrates multiple data types (co-expression, experimental, text-mining); these are not independent experimental validations |
| **Regulatory evidence** | ZEB1-AS1→ZEB1 (antisense); MYB→CDX2 cooperation; PTPN14→YAP | Literature/annotation | Regulatory relationships are inferred from literature, not demonstrated in this cohort |
| **Disease-association evidence** | INHBB (Europe PMC 41992239); NT5E (PMID 36480312); CDX2 (PMID 30631044); LINC00852 (PMID 34342374) | PubMed/Europe PMC | These are independent literature associations but do not constitute cohort replication |
| **Expression/tissue evidence** | GTEx (81/100), HPA (75/100), HumanBase (78/100) | External databases | Tissue expression patterns are contextual; they do not validate prognostic direction |
| **Genetic/clinical evidence** | ClinVar (83/100), GWAS (100/100), cBioPortal (78/100) | External databases | Variant and clinical associations are contextual; no independent cohort statistic provided |
| **Drug/therapeutic evidence** | MSLN (CAR-T trials, Europe PMC 42363170); NT5E (CD73 inhibitors) | ClinicalTrials, literature | Drug targeting does not imply therapeutic efficacy in this CRC context |
| **Published literature** | 699 PubMed + 866 Europe PMC articles retrieved | Literature search | Literature supports plausibility and mechanistic hypotheses; it does not replace cohort validation |

### Independence Assessment

- **INHBB:** The input HR/FDR and the Europe PMC literature (41992239) are genuinely independent evidence sources—one is a statistical observation, the other is published functional and clinical data. However, the literature may have used overlapping TCGA data, so independence is not complete.
- **CDX2:** The input protective direction and the extensive CDX2 literature (PMID 30631044 and many others) are independent in origin but consistent in direction.
- **Mitochondrial program:** The input HRs and STRING network evidence (CS-ACSS2-ILVBL; MT-CO1-COA3) are independent sources but STRING includes co-expression and text-mining, which may overlap with the same underlying literature.

### Conflicting Evidence

- **CCL15** shows a protective direction (HR = 0.753) in this dataset, but CCL15 is generally described as a pro-inflammatory, tumor-promoting chemokine in the literature. This conflict may reflect cell-type-specific effects (e.g., immune cell recruitment vs. tumor-cell autocrine signaling) or may be a false direction due to probe/annotation issues (the gene is listed as CCL15-CCL14|CCL15, indicating a read-through transcript).
- **DCBLD2** has direction-conflict flagged in the ledger (4 rows with mixed directions), meaning different probes may show inconsistent HRs. This reduces confidence in its risk association.
- **BCL2L14** also has direction-conflict (4 rows), warranting caution.

---

## 6. Limitations and Alternative Explanations

### Limitation 1: Tissue Composition and Tumor Purity
The most significant confounder. Bulk tumor tissue contains variable proportions of tumor cells, stromal fibroblasts, immune cells, endothelial cells, and normal epithelium. EMT genes (ZEB1-AS1, TPM4, ITGBL1) may be expressed primarily by stromal cells, not tumor cells. Mitochondrial genes may be enriched in immune cells or normal epithelium.
- **How to investigate:** Cell-type deconvolution (CIBERSORTx, quanTIseq), single-cell RNA-seq, spatial transcriptomics, or laser-capture microdissection followed by RNA-seq of tumor vs. stromal compartments.

### Limitation 2: Disease Severity and Stage Confounding
OS is influenced by stage, grade, and treatment. If the cohort includes mixed stages, the risk-associated genes may simply reflect later-stage disease rather than an independent prognostic effect. Stage information was not provided in the input.
- **How to investigate:** Stratified analysis by stage, or multivariable Cox regression adjusting for stage, grade, age, and sex. This requires additional clinical data not present in the current input.

### Limitation 3: Multiple Testing and Marginal FDRs
While 8 genes reach FDR ≤ 0.01, many others fall between 0.02 and 0.08. At these FDR levels, a substantial fraction of the "significant" genes may be false positives. The program-level interpretations are more robust than individual gene claims because they aggregate multiple genes.
- **How to investigate:** Independent cohort validation (e.g., TCGA-COAD/READ, GSE39582, or other publicly available CRC expression datasets with survival data). This was not performed in the current analysis.

### Limitation 4: Probe and Annotation Issues
The dataset contains 53 duplicated genes/probes and several direction-conflict entries (DCBLD2, BCL2L14, LOC101928747|RBMX|SNORD61). Some entries are PROBE_ identifiers without gene names, and some are read-through transcripts (CCL15-CCL14, MSANTD3-TMEFF1, MIR1248 multi-gene clusters). These may reflect cross-hybridization or annotation ambiguity.
- **How to investigate:** Confirm key findings with qRT-PCR or RNA-seq validation; filter probes by mapping quality; verify read-through transcripts with isoform-specific assays.

### Limitation 5: Association vs. Causation
All findings are associations between gene expression and OS. None of the genes are established as causal drivers of CRC prognosis in this analysis. The INHBB literature provides functional evidence, but the current dataset alone cannot establish causality.
- **How to investigate:** Functional studies (knockdown/overexpression in CRC models), organoid experiments, and in vivo metastasis models are required to move from association to causation.

---

## Summary

This CRC prognostic analysis identifies a coherent poor-prognosis program characterized by EMT/mesenchymal features (ZEB1-AS1, TPM4, ITGBL1, DCBLD2) and TGF-β/activin signaling (INHBB, PTPN14, AKT3), counterbalanced by a protective program of intestinal differentiation (CDX2, CDX1, MYB, LGALS4) and preserved mitochondrial oxidative metabolism (NDUFA9, ATP5B, CS). The most actionable priorities are: (1) deconvoluting the EMT signal to determine its cellular origin, (2) functionally validating INHBB/activin signaling as a mechanistic driver, (3) confirming CDX2 as a biomarker, (4) evaluating NT5E/CD73 as an immunotherapy-relevant target, and (5) determining whether the mitochondrial protective signal reflects tumor metabolism or tissue composition. External statistical validation in an independent cohort was not performed and is essential before any of these genes or programs can be considered validated prognostic markers.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=84, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: deepseek / deepseek-v4-flash.

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
